NAMS
HEALTHCARENewAmsterdam Pharma Company N.V. Ordinary Shares
What's Moving NAMS Today?
No stock-specific AI insight has been generated for NAMS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$31.40
Fundamentals
Trading
NAMS News
23 articles- A Look At NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price WeaknessYahoo Finance·Jun 11, 2026
- (NAMSW) Risk Channels and Responsive AllocationStock Traders Daily·Jun 11, 2026
- Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026Yahoo Finance·Jun 8, 2026
- 5 Best Non-AI Stocks to Buy According to Billionaire Stanley DruckenmillerInsider Monkey·Jun 3, 2026
- NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific SessionsYahoo Finance·Jun 3, 2026
- Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% SurgeMotley Fool·May 30, 2026
- Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could MeanMotley Fool·May 30, 2026
- Biotech NewAmsterdam to appear at two June healthcare investor eventsStock Titan·May 28, 2026
- NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in JuneYahoo Finance·May 28, 2026
- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesYahoo Finance·May 11, 2026
- NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in MayYahoo Finance·May 11, 2026
- Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?Yahoo Finance·May 8, 2026
- NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded TrendsMarketbeat·May 8, 2026
- NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsYahoo Finance·May 7, 2026
- A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib’s Phase 3 LDL C ResultsYahoo Finance·Apr 9, 2026
- NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan DruckenmillerYahoo Finance·Apr 8, 2026
- NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 8, 2026
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 2, 2026
- Here’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4Yahoo Finance·Apr 2, 2026
- Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS)Yahoo Finance·Mar 29, 2026
- NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific SessionYahoo Finance·Mar 23, 2026
- This Biotech Was Quietly Bought Before a $58 Per Share TakeoutMotley Fool·Mar 21, 2026
All 23 articles loaded
Price Data
52-Week Range
$31.40
Fundamentals
Trading
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V. is an innovative biotechnology firm dedicated to developing novel therapies for cardiometabolic diseases, utilizing its proprietary technology platform to tackle significant unmet medical needs. With a strong clinical development pipeline and a strategic focus on advancing treatment paradigms, the company is well-positioned to make impactful contributions to the healthcare landscape. Led by an experienced management team, NewAmsterdam represents a compelling investment opportunity for institutional investors looking to support transformative solutions that improve patient outcomes and drive future growth in the biopharmaceutical sector.